New PET tracer could light up pancreatic tumors
NCT ID NCT07608627
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new radioactive tracer (64Cu-DOTA-A2DM) for PET scans in people with advanced pancreatic cancer that has spread. The tracer is designed to attach to a protein called PSCA found on some pancreatic cancer cells, making them visible on the scan. The study will check the tracer's safety, side effects, and best dose in about 15 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors